Last mentioned: Feb 26, 2026
Integration Phase
Transfer of DuplexSeq equipment and IP to Scantox facilities and staff training.
Acquisition Announced
Scantox officially announces the purchase of TwinStrand's nonclinical genomics safety business.
Full Commercial Launch
Scantox expected to offer full-scale DuplexSeq services as part of its standard safety assessment packages.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive DNA sequencing technology into its preclinical CRO services. The move positions Scantox as a leader in high-precision genetic toxicology, offering pharmaceutical clients 10,000x greater sensitivity in identifying mutagenic risks.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive sequencing technology into its pre-clinical service suite. This strategic move positions Scantox as a leader in high-resolution genetic toxicology, offering pharmaceutical clients unprecedented accuracy in identifying mutagenic risks.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive DNA sequencing into its pre-clinical service portfolio. The move positions Scantox as a leader in next-generation genetic toxicology, offering 10,000x higher sensitivity than standard sequencing methods.